Compare electroCore, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 61 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
5.79
1,282.29%
-56.49
Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-56.84%
0%
-56.84%
6 Months
-58.14%
0%
-58.14%
1 Year
-13.69%
0%
-13.69%
2 Years
38.4%
0%
38.4%
3 Years
-35.93%
0%
-35.93%
4 Years
-78.49%
0%
-78.49%
5 Years
-68.1%
0%
-68.1%
electroCore, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
57.70%
EBIT Growth (5y)
9.78%
EBIT to Interest (avg)
-18.89
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.75
Sales to Capital Employed (avg)
4.52
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.38%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.74
EV to EBIT
-2.87
EV to EBITDA
-3.20
EV to Capital Employed
-10.63
EV to Sales
1.32
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-280.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 4 Schemes (3.83%)
Foreign Institutions
Held by 11 Foreign Institutions (0.87%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
7.40
6.10
21.31%
Operating Profit (PBDIT) excl Other Income
-3.30
-2.40
-37.50%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.70
-2.70
-37.04%
Operating Profit Margin (Excl OI)
-475.00%
-422.10%
-5.29%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 21.31% vs 69.44% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -37.04% vs 44.90% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
25.20
16.00
57.50%
Operating Profit (PBDIT) excl Other Income
-10.90
-17.50
37.71%
Interest
0.00
0.00
Exceptional Items
0.00
-0.50
100.00%
Consolidate Net Profit
-11.90
-18.80
36.70%
Operating Profit Margin (Excl OI)
-483.00%
-1,173.10%
69.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 57.50% vs 86.05% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 36.70% vs 15.32% in Dec 2023
About electroCore, Inc. 
electroCore, Inc.
Pharmaceuticals & Biotechnology
ElectroCore, Inc., formerly ElectroCore LLC, is a commercial-stage bioelectronic medicine healthcare company. The Company is engaged in developing non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and respiratory fields. The Company's gammaCore is a simple-to-use hand-held device that provides non-invasive dispensing therapy, which stimulates the cervical branch of the vagus nerve. The gammaCore is a non-drug treatment for adults who suffer from episodic cluster and migraine pain. The Company's target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep and pain disorders.
Company Coordinates 
Company Details
150 Allen Rd Ste 201 , Basking Ridge NJ : 07920-2977
Registrar Details






